All News
Filter News
Found 212 articles
-
It's been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
-
Shares of AnaptysBio are down more than 16% after imsidolimab failed to meet the endpoint in a Phase II trial assessing its efficacy in hidradenitis suppurativa.
-
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
8/31/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-line data from its HARP Phase 2 trial for the treatment of moderate-to-severe hidradenitis suppurativa (HS).
-
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
8/8/2022
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.
-
Gilead snapped up U.K.-based MiroBio in a $405 million deal that will bring its checkpoint agonists and discovery platform under Gilead's umbrella.
-
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/5/2022
AnaptysBio, Inc. (Nasdaq: ANAB), today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.
-
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
6/2/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference.
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
KBio Appoints Sean Stevens, Ph.D. as Chief Scientific Officer
5/5/2022
KBio today announced the appointment of Sean Stevens, Ph.D. as Chief Scientific Officer.
-
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
5/4/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
-
A roundup of last week's top clinical trial updates and news.
-
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
4/27/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive top-line data from a Phase 1 trial of ANB032, its investigational wholly owned anti-BTLA agonist antibody.
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
4/13/2022
Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors.
-
Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga
4/5/2022
Affini-T Therapeutics, Inc, a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the appointments of Michael Varney, Ph.D., and Daniel Faga to its board of directors.
-
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
-
In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.
-
It was a busy week for clinical trial announcements. Here's a look.
-
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
3/21/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately.
-
AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.
-
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
3/14/2022
AnaptysBio, Inc. (Nasdaq: ANAB), today announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints.